Interstitial pneumonitis associated with EGFR/ ALK tyrosine kinase inhibitors used in non–small cell lung cancer: an observational, retrospective, pharmacovigilance study

A bibliometric analysis of research progress on pharmacovigilance and cancer from 2002 to 2021

“…“and “alopecia” with erlotinib ( 64 ). EGFR/ALK TKIs are associated with fatal interstitial pneumonia (IP), with erlotinib-induced IP having the highest morbidity and mortality rate ( 65 ). Use of VEGF-TKI increases risk of aortic coarctation ( 66 ).…”

Hepatocellular carcinoma, vascular endothelial growth factor receptors‐targeting agents, and hypertension: A much more complicated relationship than expected

“…Lenvatinib, like other multikinase inhibitors used to treat hepatocellular carcinoma (HCC) patients, often induces hypertension, 1 due to its antiangiogenic activity, mediated by the inhibition of vascular endothelial growth factor (VEGF) receptors (VEGFRs). Indeed, a systematic review and meta‐analysis showed that the relative risk (RR) for all‐grade and high‐grade (grade 3 or more) hypertension was 2.61 and 3.35, respectively, for lenvatinib, compared with other multikinase inhibitors or placebo 2 …”

Pembrolizumab in advanced non-small cell lung cancer: safety implications of dose adjustments

“…Since these patients were dose escalated with pembrolizumab sometime between August 2020 and November 2021, it would be reasonable to deduce that all 3 patients with EGFR mutations received prior osimertinib, a 3 rd generation EGFR inhibitor that was FDA-approved in April 2018 following the FLAURA trial ( 7 , 8 ). All EGFR TKIs, including osimertinib, are well characterized to cause pneumonitis as an uncommon adverse effect ( 9 ). Additionally, in an observational study of over 20,000 patients, patients who received subsequent immunotherapy (nivolumab in this case) after EGFR-TKI had statistically higher odds of pneumonitis than those who did not get prior EGFR-TKI ( 10 ).…”